Efficacy and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial) (Ruth Sapir-Pichhadze)
Bringing a candidate Haemophilus influenzae serotype a (Hia) vaccine through late Preclinical Development to a Phase I, randomized, placebo-controlled, observer-blind trial (Zoulfia Allakhverdi on behalf of Brian Ward)
Speaker: Zoulfia Allakhverdi on behalf of Brian Ward and Ruth Sapir-Pichhadze
